Skip to main content
Erschienen in: World Journal of Urology 7/2016

28.10.2015 | Original Article

Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years

verfasst von: Liam Toner, Nathan Papa, Sani H. Aliyu, Harveer Dev, Nathan Lawrentschuk, Samih Al-Hayek

Erschienen in: World Journal of Urology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are an increasing concern regarding antibiotic resistance and their potential to cause serious infections which are difficult to treat. The purpose of this surveillance programme was to assess the incidence of ESBL in adults amongst urinary isolates, identify risk factors, and detail the antibiotic susceptibility profile in order to guide empirical treatment.

Methods

From 2006 to 2014, we reviewed 21,414 positive urine cultures for E. coli and Klebsiella sp. from a University hospital in the UK and found 1420 ESBL-positive specimens. Susceptibility testing was performed by British Society of Antimicrobial Chemotherapy disc diffusion testing. ESBL screening was performed on samples resistant to cefpodoxime and confirmed by double disc diffusion (Oxoid Ltd, Basingstoke, UK). Patient gender, age, inpatient status, and catheterisation were assessed as risk factors.

Results

ESBL production amongst E. coli urine cultures increased 44 %, from 4.6 to 6.6 % of all E. coli isolates. ESBL-positive organisms were associated with increases in drug resistance, particularly amongst fluoroquinolones, trimethoprim, and cephalexin. Multidrug resistance was a feature with 75 % of ESBL+ Klebsiella sp.-resistant ≥6 antibiotic classes. ESBL producers remained largely susceptible to carbapenems. Male gender, urinary catheterisation, inpatient status, and increasing age were identified as risk factors for ESBL infection or colonisation.

Conclusion

We demonstrate that the incidence of ESBL-producing E. coli in urine cultures is increasing and that such isolates are multidrug resistant. Carbapenems and nitrofurantoin for E. coli infections remain effective, which may guide empirical antibiotic therapy.
Literatur
1.
Zurück zum Zitat Bonkat G, Müller G, Braissant O, Frei R, Tschudin-Suter S, Rieken M, Wyler S, Gasser TC, Bachmann A, Widmer AF (2013) Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates. World J Urol 31(6):1427–1432CrossRefPubMed Bonkat G, Müller G, Braissant O, Frei R, Tschudin-Suter S, Rieken M, Wyler S, Gasser TC, Bachmann A, Widmer AF (2013) Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates. World J Urol 31(6):1427–1432CrossRefPubMed
2.
Zurück zum Zitat Briongos Figuero LS, Gómez Traveso T, Bachiller Luque P, Domínguez-Gil González M, Gómez Nieto A, Palacios Martín T, González Sagrado M, Dueñas Laita A, Pérez Castrillón JL (2012) Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract 66(9):891–896CrossRefPubMed Briongos Figuero LS, Gómez Traveso T, Bachiller Luque P, Domínguez-Gil González M, Gómez Nieto A, Palacios Martín T, González Sagrado M, Dueñas Laita A, Pérez Castrillón JL (2012) Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract 66(9):891–896CrossRefPubMed
4.
Zurück zum Zitat Cohen JE, Landis P, Trock BJ, Patel HD, Ball MW, Auwaerter PG, Schaeffer E, Carter HB (2015) Fluoroquinolone resistance in the rectal carriage of men in an active surveillance cohort: longitudinal analysis. J Urol 193(2):552–556CrossRefPubMed Cohen JE, Landis P, Trock BJ, Patel HD, Ball MW, Auwaerter PG, Schaeffer E, Carter HB (2015) Fluoroquinolone resistance in the rectal carriage of men in an active surveillance cohort: longitudinal analysis. J Urol 193(2):552–556CrossRefPubMed
5.
Zurück zum Zitat Ena J, Arjona F, Martínez Peinado C, López-Perezagua MDM, Amador C (2006) Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology 68(6):1169–1174CrossRefPubMed Ena J, Arjona F, Martínez Peinado C, López-Perezagua MDM, Amador C (2006) Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology 68(6):1169–1174CrossRefPubMed
6.
Zurück zum Zitat Frakking FNJ, Rottier W, Dorigo Zetsma JW, van Hattem J, van Hees B, Kluytmans JAJW, Lutgens SPM, Prins J, Thijsen SFT, Verbon A, Vlaminckx BJM, Cohen Stuart J, Leverstein-van Hall MA, Bonten MJM (2013) Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria. Antimicrob Agents Chemother 57(7):3092–3099CrossRefPubMedPubMedCentral Frakking FNJ, Rottier W, Dorigo Zetsma JW, van Hattem J, van Hees B, Kluytmans JAJW, Lutgens SPM, Prins J, Thijsen SFT, Verbon A, Vlaminckx BJM, Cohen Stuart J, Leverstein-van Hall MA, Bonten MJM (2013) Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria. Antimicrob Agents Chemother 57(7):3092–3099CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Gupta K, Hooton T, Naber K, Wullt B, Colgan R, Miller L, Moran G, Nicolle L, Raz R, Schaeffer A, Soper D (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52(5):e103–e120CrossRefPubMed Gupta K, Hooton T, Naber K, Wullt B, Colgan R, Miller L, Moran G, Nicolle L, Raz R, Schaeffer A, Soper D (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52(5):e103–e120CrossRefPubMed
8.
Zurück zum Zitat Hawser S, Badal R, Bouchillon S, Hoban D, Biedenbach D, Cantón R, Paterson D (2013) Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002–2010. Int J Antimicrob Agents 41(3):224–228CrossRefPubMed Hawser S, Badal R, Bouchillon S, Hoban D, Biedenbach D, Cantón R, Paterson D (2013) Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002–2010. Int J Antimicrob Agents 41(3):224–228CrossRefPubMed
9.
Zurück zum Zitat Hoban D, Lascols C, Nicolle L, Badal R, Bouchillon S, Hackel M, Hawser S (2012) Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009–2010. Diagn Microbiol Infect Dis 74(1):62–67CrossRefPubMed Hoban D, Lascols C, Nicolle L, Badal R, Bouchillon S, Hackel M, Hawser S (2012) Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009–2010. Diagn Microbiol Infect Dis 74(1):62–67CrossRefPubMed
10.
Zurück zum Zitat Kollef M (2008) Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 47(Suppl 1):S3–S13CrossRefPubMed Kollef M (2008) Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 47(Suppl 1):S3–S13CrossRefPubMed
11.
Zurück zum Zitat Ku N, Kim Y, Kim M, Song J, Oh D, Ahn J, Kim S, Kim H-W, Jeong S, Han S, Kim C, Song Y, Kim J, Choi J (2014) Risk factors for 28-day mortality in elderly patients with extendedspectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia. Arch Gerontol Geriatr 58(1):105–109CrossRefPubMed Ku N, Kim Y, Kim M, Song J, Oh D, Ahn J, Kim S, Kim H-W, Jeong S, Han S, Kim C, Song Y, Kim J, Choi J (2014) Risk factors for 28-day mortality in elderly patients with extendedspectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia. Arch Gerontol Geriatr 58(1):105–109CrossRefPubMed
12.
Zurück zum Zitat Liss MA, Taylor SA, Batura D, Steensels D, Chayakulkeeree M, Soenens C, Rao GG, Dash A, Park S, Patel N, Woo J, McDonald M, Nseyo U, Banapour P, Unterberg S, Ahlering TE, Van Poppel H, Sakamoto K, Fierer J, Black PC (2014) Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. J Urol 192(6):1673–1678CrossRefPubMed Liss MA, Taylor SA, Batura D, Steensels D, Chayakulkeeree M, Soenens C, Rao GG, Dash A, Park S, Patel N, Woo J, McDonald M, Nseyo U, Banapour P, Unterberg S, Ahlering TE, Van Poppel H, Sakamoto K, Fierer J, Black PC (2014) Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. J Urol 192(6):1673–1678CrossRefPubMed
13.
Zurück zum Zitat Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281CrossRefPubMed Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281CrossRefPubMed
14.
Zurück zum Zitat Melzer M, Petersen I (2007) Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 55(3):254–259CrossRefPubMed Melzer M, Petersen I (2007) Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 55(3):254–259CrossRefPubMed
15.
Zurück zum Zitat Osthoff M, McGuinness S, Wagen A, Eisen D (2015) Urinary tract infections due to extended-spectrum beta lactamase-producing gram-negative bacteria: identification of risk factors and outcome predictors in an Australian tertiary-referral hospital. Int J Infect Dis IJID 34:79–83CrossRefPubMed Osthoff M, McGuinness S, Wagen A, Eisen D (2015) Urinary tract infections due to extended-spectrum beta lactamase-producing gram-negative bacteria: identification of risk factors and outcome predictors in an Australian tertiary-referral hospital. Int J Infect Dis IJID 34:79–83CrossRefPubMed
16.
Zurück zum Zitat Peralta G, Lamelo M, Alvarez García P, Velasco M, Delgado A, Horcajada J, Montero M, Roiz M, Fariñas M, Alonso J, Martínez L, Gutiérrez Macías A, Alava J, Rodríguez A, Fleites A, Navarro V, Sirvent E, Capdevila J (2012) Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis 12:245CrossRefPubMedPubMedCentral Peralta G, Lamelo M, Alvarez García P, Velasco M, Delgado A, Horcajada J, Montero M, Roiz M, Fariñas M, Alonso J, Martínez L, Gutiérrez Macías A, Alava J, Rodríguez A, Fleites A, Navarro V, Sirvent E, Capdevila J (2012) Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis 12:245CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Qi C, Malczynski M, Schaeffer AJ, Barajas G, Nadler RB, Scheetz MH, Zembower TR (2013) Characterization of ciprofloxacin resistant Escherichia coli isolates among men undergoing evaluation for transrectal ultrasound guided prostate biopsy. J Urol 190(6):2026–2032CrossRefPubMed Qi C, Malczynski M, Schaeffer AJ, Barajas G, Nadler RB, Scheetz MH, Zembower TR (2013) Characterization of ciprofloxacin resistant Escherichia coli isolates among men undergoing evaluation for transrectal ultrasound guided prostate biopsy. J Urol 190(6):2026–2032CrossRefPubMed
18.
Zurück zum Zitat Sader H, Flamm R, Jones R (2014) Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009–2011). J Chemother 26(3):133–138CrossRefPubMed Sader H, Flamm R, Jones R (2014) Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009–2011). J Chemother 26(3):133–138CrossRefPubMed
19.
Zurück zum Zitat Wagenlehner FME, Cek M, Naber K, Kiyota H, Bjerklund Johansen T (2012) Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. World J Urol 30(1):59–67CrossRefPubMed Wagenlehner FME, Cek M, Naber K, Kiyota H, Bjerklund Johansen T (2012) Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. World J Urol 30(1):59–67CrossRefPubMed
20.
Zurück zum Zitat Wang A, Nizran P, Malone M, Riley T (2013) Urinary tract infections. Prim Care 40(3):687–706CrossRefPubMed Wang A, Nizran P, Malone M, Riley T (2013) Urinary tract infections. Prim Care 40(3):687–706CrossRefPubMed
21.
Zurück zum Zitat Womble PR, Dixon MW, Linsell SM, Ye Z, Montie JE, Lane BR, Miller DC, Burks FN (2014) Infection related hospitalizations after prostate biopsy in a statewide quality improvement collaborative. J Urol 191(6):1787–1792CrossRefPubMed Womble PR, Dixon MW, Linsell SM, Ye Z, Montie JE, Lane BR, Miller DC, Burks FN (2014) Infection related hospitalizations after prostate biopsy in a statewide quality improvement collaborative. J Urol 191(6):1787–1792CrossRefPubMed
22.
Zurück zum Zitat Womble PR, Linsell SM, Gao Y, Ye Z, Montie JE, Gandhi TN, Lane BR, Burks FN, Miller DC (2015) A statewide intervention to reduce hospitalizations after prostate biopsy. J Urol 194(2):403–409CrossRefPubMed Womble PR, Linsell SM, Gao Y, Ye Z, Montie JE, Gandhi TN, Lane BR, Burks FN, Miller DC (2015) A statewide intervention to reduce hospitalizations after prostate biopsy. J Urol 194(2):403–409CrossRefPubMed
23.
Zurück zum Zitat Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, Johnson AP, Pike R, Warner M, Cheasty T, Pearson A, Harry S, Leach JB, Loughrey A, Lowes JA, Warren RE, Livermore DM (2004) Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 54(4):735–743CrossRefPubMed Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, Johnson AP, Pike R, Warner M, Cheasty T, Pearson A, Harry S, Leach JB, Loughrey A, Lowes JA, Warren RE, Livermore DM (2004) Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 54(4):735–743CrossRefPubMed
24.
Zurück zum Zitat Yilmaz E, Akalin H, Ozbey S, Kordan Y, Sinirtaş M, Gürcüoglu E, Ozakin C, Heper Y, Mistik R, Helvaci S (2008) Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Chemother 20(5):581–585CrossRefPubMed Yilmaz E, Akalin H, Ozbey S, Kordan Y, Sinirtaş M, Gürcüoglu E, Ozakin C, Heper Y, Mistik R, Helvaci S (2008) Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Chemother 20(5):581–585CrossRefPubMed
25.
Zurück zum Zitat Zilberberg M, Shorr A (2013) Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000–2009. Infect Control Hosp Epidemiol 34(9):940–946CrossRefPubMed Zilberberg M, Shorr A (2013) Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000–2009. Infect Control Hosp Epidemiol 34(9):940–946CrossRefPubMed
Metadaten
Titel
Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years
verfasst von
Liam Toner
Nathan Papa
Sani H. Aliyu
Harveer Dev
Nathan Lawrentschuk
Samih Al-Hayek
Publikationsdatum
28.10.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 7/2016
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-015-1718-x

Weitere Artikel der Ausgabe 7/2016

World Journal of Urology 7/2016 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.